Improved reporting gives greater insight into the business, but investors are still left with little visibility into potential downstream value. Ginkgo needs to demonstrate that they are more than a ...

Ginkgo Bioworks (NYSE: DNA) is having a strong showing today. Specifically, the synthetic biology company's shares were up by 10.1% on heavy volume as of 9:57 a.m. ET Wednesday morning. What's behind ...

"It's a great opportunity to get to work with the PREDICTS team led by Deep Origin," said Jesse Dill, Senior Director at ...

Ginkgo Bioworks is a company with a lot of potential but also a lot of associated risk. The company is having difficulty growing revenues and is experiencing large operating losses. There are some ...

Could Ginkgo Bioworks Holdings (NYSE: DNA) one day be part of the healthcare sector's version of the "Magnificent Seven" group of high-performing stocks? It's more likely than you think. The ...

Ginkgo Bioworks announces the launch of Ginkgo Datapoints, which aims to make the training of AI models easier and more efficient. Ginkgo Bioworks shares are up more than 9% over the past week. Get 5 ...

Forbes contributors publish independent expert analyses and insights. Benjamin Wolff covers leadership insights from the world of the arts. A new technology is changing the world, turning dreams into ...

ProteoNic BV, a leading provider of premium vector technology for biopharmaceutical and viral vector production, today announced that its proprietary 2G UNic® technology has been licensed by Ginkgo ...

Ginkgo Bioworks (NYSE:DNA) stock is up more than 12% today after a strong second-quarter earnings call this morning. The DNA sequencing company clearly managed to impress investors with its strong ...

Ginkgo Bioworks announces a partnership to work with Novo Nordisk's medicines for serious chronic diseases, including diabetes and obesity. The company also announces the acquisition of AgBiome's ...